Masimo Corporation · NASDAQ:MASI
Masimo — 2025 J.P. Morgan Healthcare Conference
15 slides from Masimo's conference presentation, Jan 16, 2025
Slide 1: 2025 J.P. Morgan Healthcare Conference
2025 J.P. Morgan Healthcare Conference January 16, 2025
Slide 2: Safe Harbor Statement
Safe Harbor Statement Forward-Looking Statements: This presentation contains forward-looking statements within the meaning of federal securities laws, including, among others, statements about our expectations, plans, strategies or prospects. We generally use the words “may,” “will,” “expect,” “beli
Slide 3: Michelle Brennan, Interim Chief Executive Officer
Michelle Brennan, Interim Chief Executive Officer Ms. Brennan has served as a member of our Board since June 2023. Ms. Brennan currently serves on the boards of Cardinal Health, Inc. and Perosphere Technologies, Inc., where she sits on the Audit Committee and the Human Resources & Compensation Commi
Slide 4: Masimo At A Glance
Masimo At A Glance The Global Leader in Non-Invasive Monitoring 150+ 350+ countries where we sell engineers worldwide our products 200 million+ Top 10 U.S. Hospitals Masimo SET® is the primary pulse patients monitored each year oximetry technology for the top 10 using Masimo SET® technology U.S. hos
Slide 5: Evolution of Masimo
Evolution of Masimo Pre-2022 2022-2024 2025+ Build a best-in-class medtech Expand into consumer healthcare: Refocus on Masimo’s unique ability to business highly focused on the acquire Sound United, increase size of leverage innovation in the professional Focus professional healthcare market. R&D or
Slide 6: We Made Substantial Progress in 2024
We Made Substantial Progress in 2024 Strong Core Healthcare Growth Cost Savings Initiatives Organizational Initiatives Continue to deliver consistent and durable Cost savings initiatives already underway Driving progress toward streamlined & efficient revenue growth creating significant operating le
Slide 7: Key Priorities for 2025 & Beyond
Key Priorities for 2025 & Beyond 1 Deliver Best-In-Class Growth 2 Continue to Drive Innovation 3 Focus On Operational Efficiencies and Margin Improvement 4 Strategically Align Organization to Drive Sustainable Long-Term Growth 7
Slide 8: Deliver Best-In-Class Growth
1 Deliver Best-In-Class Growth Long Track Record of Sustained Growth Expected to Continue In 2025 and Beyond… Total Healthcare Revenue ($mm) Consumable and Service Revenue ($mm) Incremental Value of New Contracts ($mm)(2) $1,245 $410+ $1,395 $936 $776 $179 2019 2024E 2019 2024E 2019 2024E …Driven by
Slide 9: Masimo Has Been The Leading Innovator In Non-Invasive Monitoring
2 Masimo Has Been The Leading Innovator In Non-Invasive Monitoring… Preeminent Innovator in Non-Invasive Patient Monitoring Serving Highly Attractive End-Markets Preeminent Innovator in Non-Invasive Monitoring Serving Highly Attractive End-Markets Market Healthcare Rev. Market Segment Key Innovation
Slide 10: …And Will Continue to Drive Innovation
2 …And Will Continue to Drive Innovation Key Go-Forward R&D Initiatives Define and Deeper Further develop market penetration in expansion in low of hospital to high acuity care acuity care home 10
Slide 11: Focus On Operational Efficiencies and Margin Improvement
3 Focus On Operational Efficiencies and Margin Improvement Margin Optimization Initiatives Corporate Costs Research & Development Other Ongoing Efforts Optimizing corporate-level Focus organization on high- Drive operational efficiencies; spending and right-sizing conviction R&D programs with Discon
Slide 12: Strategically Align Organization to Drive Growth
4 Strategically Align Organization to Drive Growth 1 Focus Focus R&D organization on high ROIC programs with commercial viability and R&D Efforts attractive market dynamics 2 Expand and optimize manufacturing footprint in Malaysia Reduce COGS Ongoing initiatives to reduce product costs and lev
Slide 13: Preliminary FY 2024 Results & FY 2025 Guidance
Preliminary FY 2024 Results & FY 2025 Guidance Preliminary FY 2024 Results $1,395 Million More than $4.10 Healthcare Revenue $2,094 Million Non-GAAP EPS Total Revenue Above high-end of prior guidance range of +10% constant currency growth(1) $3.95 - $4.10 FY 2025 Guidance(2) $ in millions; except EP
Slide 14: Appendix
Appendix GAAP to Non-GAAP Reconciliations 14
Slide 15: GAAP to Non-GAAP Reconciliations
GAAP to Non-GAAP Reconciliations (Unaudited; in millions, except percentages)(1,2) Actual Preliminary FY 2025 Guidance(3) FY 2023 FY 2024 Low High GAAP Healthcare revenue 1,275 1,395 1,500 1,530 Constant currency revenue adjustments N/A 5 13 13 Non-GAAP Healthcare constant currency revenue $1,275 $1